Prostate Cancer International is
for 2011 by Great NonProfits
Perspective Confidentiality Disclosure Reliability Courtesy
A recent article offers data from an initial investigation of the impact of sexual motivation on the sexual health and satisfaction of men treated by radical prostatectomy (RP) for localized prostate cancer.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: masculinity, motivation, potency, radical prostatectomy, satisfaction, sexuality | Leave a Comment »
An article from Thursday’s “The Pink Sheet”, posted on the OncologySTAT web site today, is already asking questions about the potential future use of abiraterone acetate in patients with non-metastatic, castration-resistant prostate cancer (CRPC).
Filed under: Drugs in development, Management, Treatment | Tagged: abiraterone, cabazitaxel, castration-resistant prostate cancer, CRPC | 12 Comments »
An article just published on-line in Cancer has demonstrated that, in a cohort of men with a median follow-up of > 10 years, salvage radiation therapy (after first-line radical prostatectomy) reduces all-cause mortality in men with short (< 6 months) and longer (≥ 6 months) PSA doubling times at the time of initial biochemical disease progression.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: doubling time, PSA, PSADT, radiation therapy, radical prostatectomy, salvage | Comments Off
The recently published long-term results of RTOG 98-05 illustrate at least one way in which we can start to get better insight into the effectiveness and safety of new forms of treatment for localized prostate cancer as compared to older forms of treatment — without having to conduct complex and socially difficult randomized clinical trials.
Filed under: Management, Treatment | Tagged: brachytherapy, comparative, outcomes, RTOG 98-05 | 1 Comment »
Over the past few years we have seen a great deal of discussion of this or that new gene or single nucleotide polymorphism (SNP) or other set of genomic data and the potential of such information to improve the diagnosis or the prognosis of prostate cancer.
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: Diagnosis, genetics, genomics, prognosis, risk, Treatment | Leave a Comment »
We have already noted the FDA’s approval of abiraterone acetate. However, there are some interesting details that are worthy of note.
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone, approval, survival, Zytiga | 2 Comments »
The FDA has today approved abiraterone acetate (Zytiga™) for use in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) who have received prior chemotherapy containing docetaxel. A full media release is already available on the Centocor Ortho Biotech web site. There is another media release on the FDA web [...]
Filed under: Drugs in development, Management | Tagged: abiraterone | 4 Comments »
A special report just issued by the President’s Cancer Panel says that the United States urgently needs to expand research and improve understanding of cancer among minority populations.
Filed under: Diagnosis, Living with Prostate Cancer, Risk | Tagged: Diagnosis, minorities, risk | Leave a Comment »
It would be all too easy to get the idea — from the title and abstract of a recently published study — that proton beam radiation therapy (PBRT) was more effective than permanent seed brachytherapy in the treatment of men with low- and some intermediate-risk prostate cancers. This would be a very inappropriate conclusion.
Filed under: Management, Treatment | Tagged: beam, brachytherapy, comparison, EBRT, external, outcome, PBRT, proton, radiation therapy | 4 Comments »
An early release paper in the Canadian Urological Association Journal offers information on a series of patients treated with external beam radiation therapy (EBRT) as salvage therapy after biochemical progression following high-intensity focused ultrasound (HIFU) as their first-line treatment.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: EBRT, external beam radiation therapy, HIFU, high-intensity focused ultrasound, salvage | Comments Off
A review article published on-line in Nature Reviews Urology has suggested that over the past decade some 15 to 20 percent of men undergoing open radical retropublic prostatectomy (RRP) as first-line treatment for prostate cancer have an inguinal hernia as a complication of their treatment.
Filed under: Diagnosis, Management, Treatment | Tagged: complication, hernia, inguinal, open, prostatectomy, risk | Comments Off
A newly published report in the International Journal of Cancer has concluded that the non-prescription supplement ProstaCaid™ “is a promising natural complex with the potency to inhibit invasive human prostate cancer.”
Filed under: Living with Prostate Cancer, Management | Tagged: ProstaCaid | 1 Comment »
A study in the Journal of Health and Social Behavior reports data suggesting that stereotypically “macho” attitudes to masculinity are associated with a reduced likelihood of participation in preventive care.
Filed under: Diagnosis, Prevention, Risk | Tagged: machismo, preventive care, PSA, risk | 2 Comments »
Search for new and
ongoing trials on the
CTAG PCa web site